IBRX
Immunitybio Inc
NASDAQ: IBRX · HEALTHCARE · BIOTECHNOLOGY
$6.96
+0.00% today
Updated 2026-04-29
Market cap
$7.19B
P/E ratio
—
P/S ratio
63.45x
EPS (TTM)
$-0.38
Dividend yield
—
52W range
$2 – $12
Volume
27.9M
Immunitybio Inc (IBRX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+24.4%
Last 4 quarters
Revenue YoY growth
+407.0%
Most recent quarter
EPS YoY growth
+25.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-4.4%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-13.8%
2026-03-03
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-03 | $-0.06 | +45.8% | $10.44 | $9.00 | -13.8% |
| 2025-11-05 | $-0.07 | +36.4% | $2.08 | $2.12 | +1.9% |
| 2025-08-05 | $-0.10 | +9.1% | $2.41 | $2.38 | -1.2% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.11 | $-0.06 | +45.8% | $38.28M | +407.0% |
| 2025-09-30 | $-0.11 | $-0.07 | +36.4% | $32.06M | +425.1% |
| 2025-06-30 | $-0.11 | $-0.10 | +9.1% | $26.43M | +2423.9% |
| 2025-03-31 | $-0.16 | $-0.15 | +6.3% | $16.52M | +41192.5% |
| 2024-12-31 | $-0.13 | $-0.08 | +38.5% | $7.55M | +5333.1% |
| 2024-09-30 | $-0.18 | $-0.12 | +31.6% | $6.11M | +7346.3% |
| 2024-06-30 | $-0.17 | $-0.20 | -17.6% | $1.05M | +2453.7% |
| 2024-03-31 | $-0.16 | $-0.20 | -25.0% | $40000.00 | — |
| 2023-12-31 | $-0.18 | $-0.35 | -94.4% | $139000.00 | — |
| 2023-09-30 | $-0.25 | $-0.19 | +24.0% | $82000.00 | — |
| 2023-06-30 | $-0.23 | $-0.32 | -39.1% | $41000.00 | — |
Frequently asked questions
Has Immunitybio Inc beaten earnings estimates?
Immunitybio Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +24.4% over the last 4 quarters.
How does IBRX stock react to earnings?
IBRX stock has moved an average of -4.4% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Immunitybio Inc's revenue growth rate?
Immunitybio Inc reported year-over-year revenue growth of +407.0% in its most recent quarter, with EPS growing +25.0% year-over-year.